Published in Nat Rev Clin Oncol on March 30, 2011
Drug development: Raise standards for preclinical cancer research. Nature (2012) 20.64
Drug development and clinical trials--the path to an approved cancer drug. Nat Rev Clin Oncol (2012) 4.98
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol (2012) 2.70
One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett (2013) 1.49
A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Sci Transl Med (2015) 1.43
Chemistry and biochemistry of 13C hyperpolarized magnetic resonance using dynamic nuclear polarization. Chem Soc Rev (2013) 1.41
Predictive Value Tools as an Aid in Chemopreventive Agent Development. J Natl Cancer Inst (2015) 1.40
Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol (2013) 1.30
Reproducibility of research and preclinical validation: problems and solutions. Nat Rev Clin Oncol (2013) 1.20
Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate (2013) 1.15
Three-dimensional cell culture: a breakthrough in vivo. Int J Mol Sci (2015) 1.12
Appraising iniparib, the PARP inhibitor that never was--what must we learn? Nat Rev Clin Oncol (2013) 1.01
Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways. PLoS Comput Biol (2013) 1.00
Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies. Adv Drug Deliv Rev (2015) 0.91
Preclinical predictors of anticancer drug efficacy: critical assessment with emphasis on whether nanomolar potency should be required of candidate agents. J Pharmacol Exp Ther (2012) 0.87
Systematic, spatial imaging of large multimolecular assemblies and the emerging principles of supramolecular order in biological systems. J Mol Recognit (2014) 0.86
The migration ability of stem cells can explain the existence of cancer of unknown primary site. Rethinking metastasis. Oncoscience (2015) 0.86
Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24. PLoS One (2013) 0.84
Establishment of highly tumorigenic human colorectal cancer cell line (CR4) with properties of putative cancer stem cells. PLoS One (2014) 0.83
Choosing the right cell line for renal cell cancer research. Mol Cancer (2016) 0.82
A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials (2015) 0.81
Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening. Oncotarget (2015) 0.81
Automated Electrophysiological and Pharmacological Evaluation of Human Pluripotent Stem Cell-Derived Cardiomyocytes. Stem Cells Dev (2016) 0.80
Advances in toponomics drug discovery: Imaging cycler microscopy correctly predicts a therapy method of amyotrophic lateral sclerosis. Cytometry A (2015) 0.79
Bioengineered tumors. Bioengineered (2015) 0.79
Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer (2015) 0.78
Early phase clinical trials to identify optimal dosing and safety. Mol Oncol (2014) 0.78
Patient-derived xenografts: a relevant preclinical model for drug development. J Exp Clin Cancer Res (2016) 0.78
Cross-species models of human melanoma. J Pathol (2015) 0.77
Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials. Oncoscience (2015) 0.77
Manipulating the Gut Microbiota: Methods and Challenges. ILAR J (2015) 0.77
Multiple sclerosis: getting personal with induced pluripotent stem cells. Cell Death Dis (2015) 0.77
A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia (2016) 0.76
Microbiota and reproducibility of rodent models. Lab Anim (NY) (2017) 0.75
Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL. Cancer Biol Ther (2014) 0.75
Large molecular systems landscape uncovers T cell trapping in human skin cancer. Sci Rep (2016) 0.75
Threat posed by unproven drugs in medical oncology. ESMO Open (2016) 0.75
Phosphoethanolamine and the danger of unproven drugs. Ecancermedicalscience (2016) 0.75
Bioengineered Models of Solid Human Tumors for Cancer Research. Methods Mol Biol (2016) 0.75
Patterns in target-directed breast cancer research. Springerplus (2016) 0.75
3D Cell Culture in a Self-Assembled Nanofiber Environment. PLoS One (2016) 0.75
Patient-derived tumour xenografts for breast cancer drug discovery. Endocr Relat Cancer (2016) 0.75
Mitochondrial Dynamics Tracking with Two-Photon Phosphorescent Terpyridyl Iridium(III) Complexes. Sci Rep (2016) 0.75
Real-time cytotoxicity assays in human whole blood. J Vis Exp (2014) 0.75
Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors. Oncotarget (2017) 0.75
Expectations for methodology and translation of animal research: a survey of health care workers. BMC Med Ethics (2015) 0.75
DeSigN: connecting gene expression with therapeutics for drug repurposing and development. BMC Genomics (2017) 0.75
Preclinical screening methods in cancer. Indian J Pharmacol (2016) 0.75
Genetic heterogeneity of RPMI-8402, a T-acute lymphoblastic leukemia cell line. Oncol Lett (2015) 0.75
Anti-gastric cancer activity in three-dimensional tumor spheroids of bufadienolides. Sci Rep (2016) 0.75
Optimized design and analysis of preclinical intervention studies in vivo. Sci Rep (2016) 0.75
High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells. J Clin Invest (2016) 0.75
Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer. Chin Med J (Engl) (2016) 0.75
Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development - A Systematic Review. PLoS One (2015) 0.75
Training to Improve Precision and Accuracy in the Measurement of Fiber Morphology. PLoS One (2016) 0.75
Molecular and clinical implementations of ovarian cancer mouse avatar models. Chin Clin Oncol (2015) 0.75
The promises of quantitative systems pharmacology modelling for drug development. Comput Struct Biotechnol J (2016) 0.75
Developing translational medicine professionals: the Marie Skłodowska-Curie action model. J Transl Med (2016) 0.75
Nanoemulsion Formulation of a Novel Taxoid DHA-SBT-1214 Inhibits Prostate Cancer Stem Cell-Induced Tumor Growth. Cancer Lett (2017) 0.75
Feedback activation of AMPK-mediated autophagy acceleration is a key resistance mechanism against SCD1 inhibitor-induced cell growth inhibition. PLoS One (2017) 0.75
Breast cancer: challenges, controversies, breakthroughs. Nat Rev Clin Oncol (2010) 1.13
Gastrointestinal cancer: a step closer to combating acquired resistance in CRC. Nat Rev Clin Oncol (2012) 1.05
Structural adaptation of the plant protease Deg1 to repair photosystem II during light exposure. Nat Struct Mol Biol (2011) 0.98
Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol (2010) 0.93
Targeted therapies: the toxic reality of new drugs. Nat Rev Clin Oncol (2012) 0.86
Genetics: Personalized medicine and tumour heterogeneity. Nat Rev Clin Oncol (2012) 0.84
Oncology trials--the elephant in the room. Nat Rev Clin Oncol (2012) 0.84
Personalized cancer medicine: era of promise and progress. Nat Rev Clin Oncol (2011) 0.84
Bevacizumab and heart failure. Nat Rev Clin Oncol (2011) 0.83
Biomarkers: ctDNA-identifying cancer before it is clinically detectable. Nat Rev Clin Oncol (2015) 0.82
Chemotherapy: NAPOLI-1: winning scoop for metastatic pancreatic cancer. Nat Rev Clin Oncol (2015) 0.82
Genetics: tracking clonal origin of prostate cancer. Nat Rev Clin Oncol (2013) 0.81
Patients with high-risk aPl benefit from risk-adapted consolidation therapy. Nat Rev Clin Oncol (2010) 0.81
Skin cancer. Golden age of melanoma therapy. Nat Rev Clin Oncol (2014) 0.81
Genetics: In colorectal cancer, not all KRAS mutations are created equal. Nat Rev Clin Oncol (2011) 0.80
Digital infrared breast scan shows promise for detecting cancer. Nat Rev Clin Oncol (2010) 0.80
Breast cancer: ALTTO: wake-up call for setting up clinical trials. Nat Rev Clin Oncol (2013) 0.79
Targeted therapies: Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib. Nat Rev Clin Oncol (2010) 0.79
Palliative care: benefits of Liverpool Care Pathway. Nat Rev Clin Oncol (2013) 0.79
Risk factors. Oncotype DX assay predicts local recurrence in breast cancer. Nat Rev Clin Oncol (2010) 0.79
Skin cancer: less is as good as more in refractory melanoma. Nat Rev Clin Oncol (2014) 0.79
Herceptin: HERalding a new era in breast cancer care but at what cost? Nat Clin Pract Oncol (2005) 0.79
Lung cancer: Squiring immunotherapy to CheckMate. Nat Rev Clin Oncol (2015) 0.78
Genetics: predictor for prostate cancer. Nat Rev Clin Oncol (2011) 0.78
Risk factors. CD8+:FOXP3+ cell ratio is a novel survival marker for colorectal cancer. Nat Rev Clin Oncol (2010) 0.78
Nephrotic syndrome: Negative feedback loop reveals novel potential therapy. Nat Rev Nephrol (2013) 0.78
Skin cancer: Novel resistance mechanism revealed. Nat Rev Clin Oncol (2011) 0.78
Renal fibrosis: KIM-1 expression links kidney injury with CKD in mice. Nat Rev Nephrol (2013) 0.78
Screening: BRCA testing in women younger than 50 with triple-negative breast cancer is cost effective. Nat Rev Clin Oncol (2010) 0.78
Targeted therapies: the maths behind combination therapy. Nat Rev Clin Oncol (2013) 0.77
Immunotherapy: Evading immune escape: synergy of COX and immune-checkpoint inhibitors. Nat Rev Clin Oncol (2015) 0.77
Screening: CT screening for lung cancer: winner confirmed. Nat Rev Clin Oncol (2013) 0.77
Radiotherapy: Repopulating tumor cells--dying for caspase 3. Nat Rev Clin Oncol (2011) 0.77
Liver cancer: sorafenib resistance uncovered by novel RNAi screen. Nat Rev Clin Oncol (2014) 0.77
Haematological cancer: Hit the lymphoma, JAK. Nat Rev Clin Oncol (2012) 0.77
Targeted therapies: STAT3 and EGFR target resistance. Nat Rev Clin Oncol (2012) 0.77
Targeted therapies: chemotherapy-free option for relapsed patients with breast cancer. Nat Rev Clin Oncol (2011) 0.77
Pancreatic cancer: Mouse models link metabolism and deubiquitination with Kras. Nat Rev Clin Oncol (2012) 0.76
Radiotherapy: abscopal responses: pro-immunogenic effects of radiotherapy. Nat Rev Clin Oncol (2015) 0.76
New paradigms to explain metastasis. Nat Rev Clin Oncol (2011) 0.76
Prevention: MAPping out breast cancer chemoprevention. Nat Rev Clin Oncol (2011) 0.76
Lung cancer: Maintenance chemotherapy--a stitch in time saves nine? Nat Rev Clin Oncol (2012) 0.76
Haematological cancer: new standard of care? Nat Rev Clin Oncol (2013) 0.76
Prostate cancer from basal cells. Nat Rev Clin Oncol (2010) 0.76
Focus issue on biomarkers. Nat Rev Clin Oncol (2010) 0.76
Immunotherapy: a first for first-line therapy in NSCLC. Nat Rev Clin Oncol (2011) 0.76
Immunotherapy: Clonal neoantigens and immune response: a balancing act. Nat Rev Clin Oncol (2016) 0.76
Targeted therapies: Lapatinib is effective in patients with p95HER2-positive tumors. Nat Rev Clin Oncol (2010) 0.76
Immunotherapy: Adoptive cell therapy simplified. Nat Rev Clin Oncol (2013) 0.76
Clinical trials: New options for melanoma? Nat Rev Clin Oncol (2012) 0.76
Genetics: new classification for endometrial cancer puts genes in POLE position. Nat Rev Clin Oncol (2013) 0.76
Immunotherapy: Harmonizing the immune response with a cancer vaccine. Nat Rev Clin Oncol (2012) 0.76
Screening: Where does stool DNA testing FIT in the CRC screening menu? Nat Rev Clin Oncol (2014) 0.76
Targeted therapies: LUX-Lung trials-not all mutations are created equal. Nat Rev Clin Oncol (2015) 0.76
The era of personalized medicine: back to basics. Nat Clin Pract Oncol (2008) 0.76
Radiotherapy: DNA repair--a marker of late toxicity. Nat Rev Clin Oncol (2014) 0.76
Closing the controversies gap in prostate cancer? Nat Rev Clin Oncol (2014) 0.75
Genetics: New miRNA classifier distinguishes CTCL from benign skin disorders. Nat Rev Clin Oncol (2011) 0.75
Screening: Improved model for lung cancer detection. Nat Rev Clin Oncol (2013) 0.75
Genetics: BRCA2 mutation offers response and survival advantages. Nat Rev Clin Oncol (2011) 0.75
Lung cancer: OPTIMAL results for erlotinib in NSCLC. Nat Rev Clin Oncol (2013) 0.75
EPIC risk: behind the smoke-screen. Nat Rev Clin Oncol (2012) 0.75
Chemotherapy: Cisplatin more effective when given less often. Nat Rev Clin Oncol (2011) 0.75
Targeted therapies: Progress for KRAS mutant NSCLC. Nat Rev Clin Oncol (2012) 0.75
Chemotherapy: Killing vessels improves delivery. Nat Rev Clin Oncol (2011) 0.75
Breast cancer: Genetic signature trumps clinicopathological features. Nat Rev Clin Oncol (2013) 0.75
Gynaecological cancer: CLOVAR validates prognostic gene-expression signature. Nat Rev Clin Oncol (2013) 0.75
Chemotherapy: final ACT for standard of care in anal cancer? Nat Rev Clin Oncol (2013) 0.75
Patient profiling in breast cancer--is knowledge power? Nat Rev Clin Oncol (2011) 0.75
Hematology: New hope for lymphoma patients. Nat Rev Clin Oncol (2011) 0.75
Last 30 days--hitting too hard? Nat Rev Clin Oncol (2012) 0.75
Hematology: NK gene donor selection in AML. Nat Rev Clin Oncol (2011) 0.75
Bladder cancer: Gene-expression signature in urine indicates aggressive disease. Nat Rev Urol (2010) 0.75
Hematology: Rituximab improves survival for solid organ transplant recipients with PTLD. Nat Rev Clin Oncol (2010) 0.75
Skin cancer: Novel mouse model reveals strategy to delay drug resistance in melanoma. Nat Rev Clin Oncol (2013) 0.75
Immunotherapy: Novel approach for universal adoptive cell transfer therapy with improved outcome. Nat Rev Clin Oncol (2011) 0.75
Human CML stem cells insensitive to imatinib even when BCR–ABL is inhibited. Nat Rev Clin Oncol (2011) 0.75
Hematology: cast iron results for ESA use in cancer. Nat Rev Clin Oncol (2011) 0.75
Gastrointestinal cancer: turning up trumps for new CRC subtypes. Nat Rev Clin Oncol (2013) 0.75
Gynecological cancer: True progress in ovarian cancer or just the tip of the iceberg? Nat Rev Clin Oncol (2012) 0.75
Screening: Reduced breast cancer mortality rates in Europe are not due to screening. Nat Rev Clin Oncol (2011) 0.75
SSP reliability for breast cancer. Nat Rev Clin Oncol (2010) 0.75
Immunotherapy: Alphavirus vector induces immune response in advanced cancers. Nat Rev Clin Oncol (2010) 0.75
Urological cancer: TKIs strike back: complete remission in kidney cancer. Nat Rev Clin Oncol (2012) 0.75
Chemotherapy: DNA repair predicts survival in patients with NSCLC. Nat Rev Clin Oncol (2011) 0.75
Lenalidomide for multiple myeloma. Nat Rev Clin Oncol (2010) 0.75
Hematology: Allografting offers better outcomes than autografting for patients with myeloma. Nat Rev Clin Oncol (2011) 0.75
Gastrointestinal cancer: Screening cost effective, not treatment. Nat Rev Clin Oncol (2012) 0.75
Chemotherapy: Reduced incidence of major bleeds with semuloparin. Nat Rev Clin Oncol (2012) 0.75
Targeted therapies: Doxorubicin and sorafenib improves survival in patients with advanced hepatocellular carcinoma. Nat Rev Clin Oncol (2011) 0.75
CLL pathogenesis: novel microRNA/ TP53 feedback circuitry. Nat Rev Clin Oncol (2011) 0.75
Diagnosis: Gene-expression signature in urine diagnoses aggressive bladder cancer. Nat Rev Clin Oncol (2010) 0.75
Gastrointestinal cancer: Not all CRC subtypes are created equal. Nat Rev Clin Oncol (2012) 0.75
Epidemiology: Triggering a bad stimulation. Nat Rev Clin Oncol (2011) 0.75
Drug therapy: a new standard for thyroid cancer? Nat Rev Clin Oncol (2011) 0.75
Combination therapies: New prognostic factor for brain metastasis from ovarian cancer. Nat Rev Clin Oncol (2011) 0.75
Risk factors: Cachexia--skeletal muscle depletion is a prognostic factor. Nat Rev Clin Oncol (2013) 0.75